Navigation Links
First study to reveal how paracetamol works could lead to less harmful pain relief medicines

Researchers at King's College London have discovered how one of the most common household painkillers works, which could pave the way for less harmful pain relief medications to be developed in the future.

Paracetamol, often known in the US and Asia as acetaminophen, is a widely-used analgesic (painkiller) and the main ingredient in everyday medications such as cold and flu remedies. Although discovered in the 1890s and marketed as a painkiller since the 1950s, exactly how it relieves pain was unknown.

This study, funded by the UK Medical Research Council (MRC) and published online today in Nature Communications, shows for the first time the principal mechanism of action for one of the most-used drugs in the world.

The researchers from King's, with colleagues from Lund University in Sweden, have identified that a protein called TRPA1, found on the surface of nerve cells, is a key molecule needed for paracetamol to be an effective painkiller.

Dr David Andersson, from the Wolfson Centre for Age Related Diseases at King's, said: 'This is an extremely exciting finding, which unlocks the secrets of one of the most widely-used medicines, and one which could impact hugely on the development of new pain relief drugs.

'Paracetamol is the go-to medicine for treating common aches and pains, but if the recommended dose is significantly exceeded it can lead to fatal complications.

'So now we understand the underlying principal mechanism behind how this drug works, we can start to look for molecules that work in the same way to effectively relieve pain, but are less toxic and will not lead to serious complications following overdose.'

The team of researchers used a 'hot-plate' test to observe the effects of paracetamol in mice. This involved measuring the number of seconds it takes for a mouse to withdraw its paw from a slightly hot surface. They found that paracetamol increased the time it took for mice to withdraw their paw, showing that the drug reduced the heat-induced pain.

The scientists then carried out experiments to observe what happened when a protein called TRPA1 was not present at all in the mice. They found that when they removed the TRPA1 protein and repeated the hot-plate test, the paracetamol had no analgesic effect. This identifies the protein as a key molecule needed for paracetamol to be an effective painkiller.

However, paracetamol on its own does not activate the TRPA1 protein. The study showed that when paracetamol is administered, a break-down product called NAPQI is formed in the spinal cord (where 'painful' information is processed). This product is also formed in the liver and is responsible for the toxic side effects seen following overdoses.

Furthermore, they demonstrated that other compounds that, unlike NAPQI, are not toxic can activate TPRA1 in the spinal cord when injected into mice. Because these compounds are not reactive, they are less likely to be harmful.

Professor Stuart Bevan, co-author from King's, said: 'What we saw happening in the mice was that the break-down product formed from paracetamol in turn stimulates a protein found on the surface of nerve cells called TRPA1. When this protein was activated, it appeared to interfere with the transmission of information from that nerve cell to other nerve cells, which would normally send a signal up to the brain, signalling pain. So in this case the NAPQI product that was formed from paracetamol acted on the TRPA1 protein to reduce transmission of information from pain-sensing nerves to the brain.

'These results are surprising because previous studies have shown that TRPA1 can actually produce pain, coughs and hypersensitivities it is the receptor for many common irritants like onion, mustard and tear gas. So our discovery shows for the first time that the opposite is in fact true this protein is a novel mechanism of action for a painkiller.'

The researchers say that if they can identify other analgesic compounds similar to paracetamol that use the same TRPA1 pathway to prevent pain signals sent by nerve cells to the brain, it is possible that they can find a compound that does not have toxic effects and will reduce the risk of overdose.

Dr Andersson concludes: 'This study validates TRPA1 as a new target for pain relief drugs. Many targets have been identified in the past, but as paracetamol is a medicine that we know works well in humans, this gives us a head-start in looking for effective molecules that utilise the same pathways but are less harmful.'

Contact: Katherine Barnes
King's College London

Related biology news :

1. West coast log, lumber exports in first 9 months of 2011 surpass 2010 totals
2. Paleontologist describes large nest of juvenile dinosaurs, first of their genus ever found
3. Worlds first stem cell bandage in human clinical trials
4. NASAS NPP satellite acquires first ATMS measurements
5. Berkeley Lab researchers create first of its kind gene map of sulfate-reducing bacterium
6. First UN carbon offset project certified
7. First use of high-field MRI in developing brain reveals previously undetectable injuries
8. Poor sleep quality in first, third trimesters linked to preterm births
9. Research team clarifies mechanics of first new cell cycle to be described in more than 20 years
10. Scientists measure dream content for the first time
11. A*STAR scientists first to identify stem cell key to lung regeneration
Post Your Comments:
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology: